Introduction: Accurate assessment and monitoring of the therapeutic efficacy of locally advanced prostate cancer remains a major clinical challenge. Contrary to prostate biopsies, circulating tumor cells (CTCs) are a cellular source repeatedly obtainable by blood sampling and could serve as a surrogate marker for treatment efficacy. In this study, we used size-based filtration to isolate and enumerate CTCs from the blood of 20 patients with high-risk (any one of cT3, Gleason 8-10, or prostate-specific antigen4 20 ng/ml), nonmetastatic, and treatment-naive prostate cancer before and after androgen deprivation therapy (ADT) and radiation therapy (RT).
Introduction
Prostate cancer is the most common noncutaneous malignancy in Canadian men with 25,500 men diagnosed annually (Canadian Cancer Society's Steering Committee 2010). The vast majority of patients present with localized prostate cancer that is commonly stratified into low-, intermediate-, and high-risk disease based on clinical characteristics [1, 2] . Treatment options for high-risk patients include radical prostatectomy or combined androgen deprivation therapy (ADT) and radical radiotherapy (RT). Because of the widely varying prognoses among patients within the high-risk classification, there is an urgent need for new, more accurate, and noninvasive prostate cancer biomarkers [3] . Currently, the serum prostate-specific antigen (PSA) is the most frequently used biomarker in the diagnosis and treatment of prostate cancer. However, there is no reliable method of differentiating PSA produced by cancer vs. normal prostate tissue. As a result, PSA monitoring in patients after RT has the potential for inaccuracies because the prostate gland is still intact and continues to produce PSA [4] . In addition, many patients thought to have disease recurrence based on rising PSA levels after radiotherapy do not harbor any disease at all after longer follow-up [5] . However, despite the inaccuracies of PSA to reflect the status of the prostate cancer [6, 7] , it remains an important parameter in oncological decision-making [1] .
Ever since Thomas Ashworth [8] first observed blood circulating tumor cells (CTCs) in 1869, there has been speculation that these cells may provide useful information on the primary tumor mass. CTCs have been identified as a new emerging biomarker for prostate cancer and may provide a wealth of biomarker data to aid in prognosis and disease monitoring of patients before and after treatment [9] [10] [11] [12] . Few studies have been published examining the response of CTC after treatment with RT in patients with localized prostate cancer [13] .
Using Food and Drug Administration-approved CellSearch as a primary method of the isolation of CTCs, enumeration of CTCs in patient blood has been proposed as a potential prognostic biomarker [14, 15] . Although the CellSearch is simple and quick, this antigen-based procedure may preselect for certain CTC subpopulations. The targeted epithelial surface marker EpCAM may not be expressed in sufficient quantities in some CTCs, and those CTCs are inevitably missed [16] .
In this study, we have used a filter device (ScreenCell) for size-based isolation of CTCs [17] . This method has been shown to isolate 91.2% of cells in spiked samples while allowing passage of 99.9% of common blood cells [17] , and permitting a morphology-based identification of CTCs [18] .
A total of 3 ml of blood was collected from the patients with high-risk prostate cancer before treatment (þ0m), after 2 months of ADT (þ2m), and 2 months after the final fraction of RT (þ6m). We enumerated CTCs in the blood of these patients and performed 3D telomere-specific telomere fluorescence in situ hybridization on isolated CTC. Recent research [19, 20] has shown in prostate cancer cell lines that the androgen receptor is necessary for the proper functioning of telomeres. Meeker et al. [21] have showed that telomere shortening is an early event in prostate tumorigenesis. Similarly, we have previously shown that 3D organization of telomeres is altered in cancer cells and can serve as an early prognostic tumor marker [22] [23] [24] [25] [26] [27] . Here, we provide the first evidence that 4 key parameters of 3D telomere architecture and early indicators of genomic instability (nuclear telomere distribution, presence/absence of telomere aggregates, telomere numbers per nucleus, and telomere size) allow us to stratify our patients with high-risk prostate cancer into 3 distinct groups based on the early dynamics of CTC 3D telomere analysis during ADT [23, [28] [29] [30] 22 ].
Materials and methods

Patients and isolation of CTCs
A total of 20 patients diagnosed with localized high-risk prostate cancer enrolled in the study. Tumors were considered nonmetastatic in patients with negative results in bone scan (Tc-99m-methylene diphosphonate [MDP] ) and computed tomography scan of the chest, abdomen, and pelvis. High-risk prostate cancer was defined as having either cT3, Gleason score 8 to 10, or PSA 4 20 ng/ml [1] ). This study was approved by the University ethics committee (University of Manitoba Ethics Protocol Reference no. H2011:336). Blood (9 ml) was collected in Vacutainer blood collection tubes (with EDTA as anticoagulant) and processed within 2 hours. Patient blood was processed using the ScreenCell filter method for the separation of prostate CTC [17] . Briefly, patient blood (3 ml) was precleared for 8 minutes with 4 ml of red blood cells' lysis buffer and remaining cells were prefixed before ScreenCell (7.50 Ϯ 0.36 μm pore size) filtration. Filters with captured cells were stored at 41C for up to 3 months until used. As a control, blood from 3 healthy female volunteers was processed through the ScreenCell apparatus ( Supplementary Fig. S2 ).
Enumeration of prostate CTC
Filters were imaged on a Zeiss AxioImager Z2 microscope with a Plan-APOCHROMAT Â40 objective (Zeiss, Oberkochen, Germany). Images were acquired using GenASIs software (ASI, Vista, CA, USA) and then exported using the Tagged Image File (tif) Format. To calibrate parameters used in identifying CTCs, sample images were manually processed by 2 observers. Prostate, prostate CTCs on top of the filter were distinguished from remaining few lymphocytes and other main blood cells captured according to cell shape and nuclear size [31] and features (nuclear size, circularity, and solidity) common to CTCs, were extracted. Using a python algorithm, the tif images were converted into binary images and segmented with a watershed algorithm. CTCs were identified by features they shared with the test group.
Androgen receptor immunocytochemistry
Filters containing the trapped cells were fixed for 10 minutes in 3.7% formaldehyde/1X PBS (Sigma, Oakville, Ontario, Canada) at room temperature. Filters were washed 3 times 5 minutes each in 1X phosphate-buffered saline (PBS)/50 mM MgCl 2 and blocked at 371C for 30 minutes in 4X SSC (0.6 M NaCl; 0.06 M sodium citrate)/4% bovine serum albumin (BSA, all Sigma). A FITC-labeled mouse monoclonal antibody raised against amino acid residues 299 to 315 of the human androgen receptor (AR-441; Santa Cruz, CA, USA) was applied at 1:50 (20 ng/μl) and allowed to incubate for 10 minutes at 371C in a humidified chamber. Excess antibody was removed in 3Â washes with 1X PBS/ 50 mM MgCl 2 for 5 minutes each at RT. Filters were dehydrated in an ethanol series (70%, 90%, and 100%), air dried, and attached to microscopy slides with clear nail polish. Slides were then counterstained with DAPI (Sigma), mounted with VECTASHIELD (Vector Laboratories, Burlington, Ontario, Canada) and imaged with a Zeiss Z1 microscope using a Â63 oil immersion objective with NA of 1.4 and AxioVision Software (Zeiss, Jena, Germany).
Quantitative fluorescent in situ hybridization
For quantitative fluorescent in situ hybridization, cells on the filters were incubated in 1X PBS for 5 minutes followed by a 10-minute fixation in 3.7% formaldehyde/1X PBS and 3Â washes in 1X PBS for 5 minutes each. Filters were treated with 50 μg/ml pepsin (Sigma) in 0.01 M HCl for 10 minutes at 371C, 1Â washed in 1X PBS for 5 minutes followed by postfixation for 10 minutes in 3.7% formaldehyde/1X PBS and 3Â washes in 1X PBS for 5 minutes each. Filters were dehydrated in an ethanol series and air dried. Fluorochrome-coupled (Cy3) Telomere PNA probe (DAKO) was applied (5 ml probe/slide) and, after denaturation at 801C for 3 minutes, hybridization was done for 2 hours at 301C. Slides were washed in 70% deionized formamide (Sigma) in 10 mM Tris pH 7.4 for 15 minutes, rinsed in 1X PBS and once each in 2X SSC (5 min at 551C), 0.1X SSC and 2X SSC/0.05% Tween-20 at RT. Filters were again dehydrated and air dried. Filters were removed from the metal support ring using an 8-mm biopsy punch, placed on a new slide, DAPI stained, mounted with VECTASHIELD (Vector Laboratories) with a coverslip.
3D telomere imaging
Slides were imaged on a Zeiss AxioImager Z2 microscope with a Zeiss AxioCam MRmm Rev 3 digital camera using AxioVision Release 4.8.2 (Zeiss, Jena, Germany). A Cy3 filter was used to detect the Cy3 probe nuclear hybridization to telomeric repeats at an exposure time of 500 milliseconds. Exposure times for the DAPI filter differed between slides. a total of 80 focal planes spaced 200 nm apart were imaged to create a 3D nuclear images of the CTCs and lymphocytes on the filter. Images were deconvolved using a constrained iterative algorithm [32] . For each patient sample, 30 CTCs and 30 lymphocyte (used as internal controls) nuclei were analyzed using our TeloView software [33] . TeloView is proprietary to 3D Signatures Inc., and was used with the company's permission. Each cell was analyzed for intensity of signal, presence of telomere aggregates (2 signals that cannot be resolved owing to proximity and defined as a signal with intensity greater than the standard deviation of signal intensity for that cell), number of signals per nucleus, and nuclear volume. These measurements were determined for CTCs from each patient isolated at different time points during their treatment (Fig. 2 ).
Nonsubjective ranking of changes in number of short telomeres
Rather than relying on a strict visual method of qualifying which patient fell into which group, we developed a way to compare the histograms using the difference between the peaks of each curve and continuing to plot the difference in each bin count until both curves reached a consistent count of 0 signals. The slope of this difference plot yielded a single unitless number that allowed for a way to place each sample into 1 of the 3 groups which, for the initial 20 samples, faithfully reproduced the results of the visual analysis and allowed for nonsubjective quantification of the groups. This method recapitulates the ranking of patient samples based upon changes in the number of short telomeres (o20,000 AU) from the þ0m to þ2m and þ2m to þ6m time points (Spearman's ρ ¼ À0.8436 and À0.8466, respectively), while also allowing us to represent any changes within the 0 to 20,000 AU range itself (see patient MB0393PR [ Supplementary Fig. S1 ] as example). Patients scoring more than 1 Â 10 À3 were placed in group 1, those scoring between 1 Â 10 À3 and À1 Â 10 À3 were placed in group 2, and those scoring less than À1 Â 10 À3 were placed in group 3 ( Fig. 3i-iii, respectively) .
Results
High-risk prostate cancer CTCs express androgen receptor
We tested 5 representative patient samples before treatment (þ0m) for the presence of androgen receptor-positive CTCs captured on the filter. All samples analyzed contained large, androgen receptor-positive cells (Fig. 1) . We observed both intersample and intrasample variability in the level of fluorescent intensity. Our results were consistent with those described earlier [34] .
Treatment segregates high-risk prostate cancer patients into 3 distinct CTC 3D telomere profiles
Based on 3D telomere architecture of their CTCs post-ADT at 2 months, patients were classified into 3 groups. The first group, at baseline (þ0m, untreated), showed a large number (peak count 490) of shorter telomeres 3 . Representative examples of telomere length profiles of a patient assigned to group 1 (i), group 2 (ii), and group 3 (iii). In each graph, the telomere length is shown in arbitrary units of fluorescence (AU) Baseline profile is demarcated by diamonds, post-androgen deprivation therapy in triangles, and post-RT in squares. Insets A and B: plots of the differences in the counts of the relevant histogram bins between time points (þ0m to þ2m and þ2m to þ6m, respectively).
(o20,000 AU) that decreased post-ADT (þ2m) and remained at this level at the post-RT (þ6m) time point (Figs. 3i and 4) . The second patient group showed CTC with a moderate number (peak count 90o475) of shorter telomeres at baseline (þ0m) and these telomeres remained stable in CTC collected at post-ADT (þ2m) and post-RT (þ6m; Figs. 3ii and 4). Patient group 3 displayed CTC with a moderate-to-small number (peak count 75o450) of shorter telomeres at baseline (þ0m) but increased markedly post-ADT (þ2m) but returned back to baseline short telomeres numbers post-RT (þ6m; Figs. 3iii and 4) . Patients with CTC classified as group 1 and 2 showed little change in 3D telomere architecture in response to RT. This correlated with relatively stable numbers of shorter telomeres in their CTC at the post-ADT (þ2m) and post-RT (þ6m) time points (Table 3) . By contrast, CTC derived from patient group 3 responded to RT with a sharp decrease in the number of shorter telomeres (Table 3 ). This decrease in shorter telomeres was made possible by the increase in shorter telomeres observed between the þ0m and þ2m post-ADT time points (Figs. 3i and 4) .
CTC enumeration and telomere profiles
We determined the number of CTCs before and after onset of treatment to assess whether ADT and RT could affect CTC levels in the blood of patients with high-risk prostate cancer.
The ScreenCell approach gave a minimum concentration of 14.7 CTCs/ml and a maximum concentration of more than 250 CTCs/ml in the high-risk patient blood.
Before treatment, the numbers of CTCs detected varied widely and ranged from 295.7 to 28.0 cells/ml per patient (Table 1) . Although 65% (13/20) of patients showed a decrease in the number of CTCs from baseline to post-ADT (þ2m) (Table 2), this decrease was not statistically significant across all 20 patients. Post-RT between the þ2 and þ6-month time points, we observed a decrease in CTC in 70% (14/20) of patients (Table 2 ), but again this decrease was not statistically significant across all 20 patients with high-risk prostate cancer.
When we tested the CTC enumeration data against the values obtained from our nuclear profiles, we identified a negative correlation between CTC numbers determined before any treatment and the average telomeric intensity of each sample (R 2 ¼ 0.708). However, no such correlation between CTC counts and telomere intensity was observed with the addition of ADT and RT (Table 3) .
PSA levels did not discriminate patients with high-risk prostate cancer
There was no significant correlation between PSA levels and either CTC numbers or 3D nuclear parameters at any time point (data not shown). 
Discussion
Prostate cancer is a disease of genomic instability [35] with telomere shortening as an early event [21] . The 3D telomere analysis measures genomic instability and it may be a promising biomarker for treatment response in patients with high-risk prostate cancer who are undergoing ADT and RT. The detection of shorter telomeres is associated with increased occurrence of lethal prostate cancer and decreased survival times [36] . To our knowledge, the current study is the first to investigate the nuclear 3D telomere architecture in CTCs derived from patients with nonmetastatic high-risk prostate cancer before, post-ADT, and post-RT. CTCs isolated before treatment could be divided into 3 distinct telomere signatures. Remarkably, CTCs underwent distinct dynamic changes in their 3D telomere signatures unique to each group after ADT and RT.
Recent studies have provided a nuanced view of the clinical value of CTCs collected from peripheral blood of patients with prostate cancer [37] [38] [39] [40] [41] [42] . Emerging evidence suggests that the enumeration of CTC may serve as an early predictor of survival and a sensitive biomarker for therapeutic efficacy in patients with metastatic castrationresistant prostate cancer [43, 44, 14, [45] [46] [47] [48] . However, CTC enumeration may not be an effective biomarker in patients with localized prostate cancer [43, 49, 50] . In the present study, we have used the ScreenCell filter system for sizebased separation of CTCs from whole blood of patients with nonmetastatic high-risk prostate cancer. Captured CTCs were subjected to 3D telomere analysis to determine their nuclear 3D telomere signatures before treatment and to capture dynamic changes to their 3D telomere profiles post-ADT and post-RT.
CTCs provide a window into blood-borne metastasis, as they are shed into the circulation by primary or metastatic tumors or by both. However, the ability of CTCs to successfully generate metastases is a multifactorial process and promoted by molecular factors aiding CTC cluster formation [51] . CTCs may also provide insight into the genetics of the primary prostate tumor [52, 41] and, contrary to CTC enumeration, we show here that nuclear 3D telomere architectural analysis is highly sensitive in detecting cellular events that affect the genome stability in CTCs. Thus, 3D telomere analysis of CTCs may prove to be a valuable tool in monitoring treatment response in patients with nonmetastatic high-risk prostate cancer. Early results 6 months into our prospective study on 3D telomere profiles in CTC of patients with nonmetastatic high-risk prostate cancer challenge the usefulness of PSA serum levels and CTC blood counts early after treatment as both parameters were uniform among this patient group. This was in sharp contrast to the 3 distinct telomere signatures we discovered in CTCs of the same patients. Furthermore, each of the 3 CTC groups responded to ADT and RT with different changes to telomere profiles, thus, providing a unique insight into a hitherto unknown complexity by which high-risk prostate cancer cells adapt to these treatments. We showed previously in multiple cancer models that 3D telomere architectural changes are an early predictor of disease outcome and patient survival [53] [54] [55] [56] . In fatal glioblastoma brain tumor, we identified a direct correlation between time to progression, median survival, and nuclear telomere architecture, thus, linking 3D telomere organization with disease progression and patient survival time [53] . Although the 6-month post-RT time point as the current cutoff point is too early to conclude disease outcome in our prospective study, our data allowed us to assess the effects of ADT and RT on 3D telomere architecture of captured CTCs over time.
Remarkably, CTCs of the 3 telomere signature groups responded to ADT and RT treatment with distinct dynamic changes in 3D telomere signature unique to each group. Based on our 3D telomere analysis, group 2 may qualify as a nonresponder as telomere profiles did not change significantly from pretreatment to post-ADT and post-RT. ADT treatment resulted in a dramatic decrease in the number of telomeres with an intensity less than 20,000 AU in CTC of patient group 1. This telomere phenotype remained stable post-RT suggesting that CTCs of these patients reflected the outcome of a selective process in which ADT favored the survival of androgen receptor-independent prostate cancer cell subpopulations. Intriguingly, this 3D telomere profile remained unaltered despite radiation-induced cell death, as reflected in the continued decline in PSA levels in these high-risk patients that began during ADT. Similar to group 1, the observed post-ADT boost in group 3 of a CTC population with increased telomere number and size may reflect a positive selective pressure of ADT in favor of ADT-resistant clones within the primary prostate tumor. However, contrary to patients in group 1, the significant decline in 3D telomere signals upon RT indicated the presence of a radiation-sensitive and ADT-selected CTC population in group 3. The fact that ADT treatment revealed CTCs at opposite ends of the spectrum with respect to radiation-inducible telomere signature changes in groups 1 and 3 patients may have important clinical implications. The ability of cancer cells to survive specific threats, i.e., ADT and RT, involves changes in 3D telomere architecture and reflects the effects of complex cellular processes aimed at preserving genomic stability and, thus, ensuring tumor cell survival. The effect of ADT and RT on specific 3D telomere profiles may reflect the evolution of heterogeneous prostate tumor subclones. This likely does not only involve telomere architectural changes but also includes the selection of cell clones more able to dissociate from the primary tumor, as we observed a relatively steady CTC count despite a decline in PSA levels across all 3 groups upon treatment. The cellular mechanisms that govern the dynamic telomere alterations in these patients are currently unknown.
It is important to recognize that the observed heterogeneity in telomere phenotype pretherapy and posttherapy was limited to 3 discreet CTC 3D telomere signatures unique for each patient. The effect these 3 CTC telomere populations will have on patient survival awaits future analysis. Our 3D telomere results are consistent with the observation that ADT/radiotherapy combination therapy produces a synergistic effect (see Ref. [57] for review) not seen with either treatment alone. Importantly, our data also predict that only one-third (6/20, 30%) of patients with nonmetastatic high-risk prostate cancer will be able to fully benefit from a synergistic ADT/radiotherapy treatment. 3D telomere analysis offers an imminent detection method to capture these patients early during their treatment cycle. In summary, our study identified CTCs with 3 unique 3D telomere profiles among patients with localized high-risk prostate cancer. The distinct telomere dynamics in each patient group in response to treatment provides a strong rationale for the use of 3D telomere analysis on CTCs as a way to monitor treatment response. Future studies would examine whether such monitoring would enable the choice of individualized treatment options for patients with nonmetastatic high-risk prostate cancer [58] .
